OSCR

Overexpression of miR-219 as a potential therapeutic strategy of glioblastoma cells in vitro.

Overview

Authors: Maja Petrović1, Simona Lapčević2, Ivana Z Matić1, Luka Bojić2, Marina Nikitović1, Tatjana Stanojković1, Danijela Stanisavljević Ninković2
  1. Institute for Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia
  2. Institute of Molecular Genetics and Genetic Engineering University of Belgrade, Vojvode Stepe 444a, Belgrade, Serbia
Journal: Scientific reports, volume 16, issue 1, article 25942
Dates: received 11 February 2026; accepted 3 June 2026; published online 8 June 2026
Type: Research article · Language: English
License: CC BY-NC-ND
Identifiers: DOI 10.1038/s41598-026-56920-9 · PMID 42252325 · PMCID PMC13486710 · OpenAlex W7163824497
Open access: gold, a free copy (OpenAlex)
Categories: human (organism), other condition (population), cellular / molecular (subfield)
Methods: Statistics, Evoked potentials, Connectivity
Keywords: Glioblastoma, miR-219, Radiosensitivity, Temozolomide, Irradiation, Tumor suppressor, Cancer, Oncology
MeSH: Brain Neoplasms*, Glioblastoma*, MicroRNAs*, Antineoplastic Agents, Alkylating, Apoptosis, Cell Line, Tumor, Cell Proliferation, Dacarbazine, Gene Expression Regulation, Neoplastic, Humans, Temozolomide (* major topic)
Topic: MicroRNA in disease regulation (Cancer Research, Biochemistry, Genetics and Molecular Biology), according to OpenAlex
Funding: University of Belgrade – Faculty of Medicine (200110); Wellcome Trust (200110); Ministry of Education, Science, and Technological Development of the Republic of Serbia (451-03-136/2025-03/200042, 451-03-136/2025-03/ 200043)
Citations: not cited yet (Europe PMC); 39 references in the paper

Abstract

The abstract is not reproduced here: the paper's license (CC BY-NC-ND) does not allow it. Read it in the paper, at the publisher or on Europe PMC.

Code

The paper links to its data and to no code of its authors: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Other data links

Data availability statement

The paper has a data availability statement. Its license (CC BY-NC-ND) does not allow reproducing it here; in short, from what the harvester recognized in it:

  • no repository, dataset or request procedure was recognized in it

Read it in the paper: doi.org/10.1038/s41598-026-56920-9.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 7 authors, 8 keywords, 11 MeSH terms, 3 funders, 39 references.

Cite

This paper

Petrović, M., Lapčević, S., Matić, I. Z., Bojić, L., Nikitović, M., Stanojković, T., & Stanisavljević Ninković, D. (2026). Overexpression of miR-219 as a potential therapeutic strategy of glioblastoma cells in vitro. Scientific reports, 16(1), 25942. https://doi.org/10.1038/s41598-026-56920-9

BibTeX

@article{petrovic2026overexpression,
author = {Petrović, Maja and Lapčević, Simona and Matić, Ivana Z and Bojić, Luka and Nikitović, Marina and Stanojković, Tatjana and Stanisavljević Ninković, Danijela},
title = {{Overexpression of miR-219 as a potential therapeutic strategy of glioblastoma cells in vitro}},
journal = {Scientific reports},
year = {2026},
month = jun,
volume = {16},
number = {1},
pages = {25942},
publisher = {Nature Publishing Group},
issn = {2045-2322},
doi = {10.1038/s41598-026-56920-9},
url = {https://doi.org/10.1038/s41598-026-56920-9},
pmid = {42252325},
pmcid = {PMC13486710}
}

RIS

TY - JOUR
AU - Petrović, Maja
AU - Lapčević, Simona
AU - Matić, Ivana Z
AU - Bojić, Luka
AU - Nikitović, Marina
AU - Stanojković, Tatjana
AU - Stanisavljević Ninković, Danijela
TI - Overexpression of miR-219 as a potential therapeutic strategy of glioblastoma cells in vitro
T2 - Scientific reports
J2 - Sci Rep
PY - 2026
DA - 2026/06/08
VL - 16
IS - 1
SP - 25942
SN - 2045-2322
PB - Nature Publishing Group
DO - 10.1038/s41598-026-56920-9
UR - https://doi.org/10.1038/s41598-026-56920-9
LA - en
ER -

CSL-JSON

{
"id": "10.1038/s41598-026-56920-9",
"type": "article-journal",
"title": "Overexpression of miR-219 as a potential therapeutic strategy of glioblastoma cells in vitro",
"container-title": "Scientific reports",
"author": [
{
"family": "Petrović",
"given": "Maja"
},
{
"family": "Lapčević",
"given": "Simona"
},
{
"family": "Matić",
"given": "Ivana Z"
},
{
"family": "Bojić",
"given": "Luka"
},
{
"family": "Nikitović",
"given": "Marina"
},
{
"family": "Stanojković",
"given": "Tatjana"
},
{
"family": "Stanisavljević Ninković",
"given": "Danijela"
}
],
"container-title-short": "Sci Rep",
"volume": "16",
"issue": "1",
"page": "25942",
"DOI": "10.1038/s41598-026-56920-9",
"PMID": "42252325",
"PMCID": "PMC13486710",
"ISSN": "2045-2322",
"publisher": "Nature Publishing Group",
"URL": "https://doi.org/10.1038/s41598-026-56920-9",
"language": "en",
"issued": {
"date-parts": [
[
2026,
6,
8
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.3389/fgene.2022.832742
Gene Expression Profiling of Glioblastoma to Recognize Potential Biomarker Candidates.
Journal: Frontiers in genetics
In common: NCBI GEO GSE90604, other condition
[2] doi:10.1186/s11658-025-00765-z
NT2-derived astrocyte-neuron co-culture reflects physiological relevance and offers research validity.
Journal: Cellular & molecular biology letters
In common: cellular / molecular, 2 references
[3] doi:10.1038/s41420-025-02517-6
Androgen receptor inhibition sensitizes glioblastoma stem cells to temozolomide by the miR-1/miR-26a-1/miR-487b signature mediated WT1 and FOXA1 silencing.
Journal: Cell death discovery
In common: other condition, cellular / molecular, 2 references
[4] doi:10.1186/s12885-023-11131-7
CRISPR-Cas9 identifies growth-related subtypes of glioblastoma with therapeutical significance through cell line knockdown.
Journal: BMC cancer
In common: other condition, cellular / molecular, 2 references
[5] doi:10.3390/ijms27167240
1-Piperidine Propionic Acid Inhibits PAR2/SerpinB3 Signaling and Reduces Glioblastoma Tumor Aggressiveness.
Journal: International journal of molecular sciences
In common: other condition, cellular / molecular, 2 references
[6] doi:10.3390/genes17050511
Machine Learning-Based Classification of Gliomas and Tumor Grades with SHAP-Guided Feature Interpretation.
Journal: Genes
In common: other condition, cellular / molecular, 2 references
[7] doi:10.1038/s41420-026-03035-9
Deciphering the STAT3-PXN positive feedback loop in GBM, IDH-wildtype: transcriptional regulation and inhibition of YB-1 ubiquitination.
Journal: Cell death discovery
In common: other condition, cellular / molecular, 2 references
[8] doi:10.1007/s00018-025-05687-9
Assessing the diagnostic, prognostic, and therapeutic potential of the somatostatin/cortistatin system in glioblastoma.
Journal: Cellular and molecular life sciences : CMLS
In common: other condition, 2 references
[9] doi:10.1038/s41598-026-45845-y
Identification of natural FGFR3 inhibitor for glioma using integrated computational and microRNA regulatory analysis.
Journal: Scientific reports
In common: other condition, cellular / molecular, 1 reference
[10] doi:10.1186/s12915-024-01879-0 [code]
Targeting of REST with rationally-designed small molecule compounds exhibits synergetic therapeutic potential in human glioblastoma cells.
Journal: BMC biology
In common: other condition, cellular / molecular, 1 reference

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.